AIs can be divided into two groups based on their chemical structure: steroidal (analogs of androstenedione, exemestane, formestane, and testolactone), which provide irreversible aromatase inhibition, and non-steroidal (anastrozole and letrozole), which provide reversible inhibition (Ahmad, 2015)
The FDA has announced a two-day public meeting of its Pharmacy Compounding Advisory Committee (PCAC) on July 2324, 2026, to formally evaluate whether seven bulk drug substances should be added to the Section 503A Bulk Drug Substances List (the 503A Bulks List)
It accelerates wound healing, reduces inflammation, and promotes angiogenesis (new blood vessel formation)
Higher doses dont necessarily improve results and may increase the risk of side effects
peptides used in peptide therapy are a different category